{
  "docId": "019de070-35c1-7439-bbdc-1b157563e1ac",
  "docSlug": "efb4ac2b8ef2465cd20aa5f0f0b26fe6",
  "documentTitle": "Poseida Therapeutics | IPO Presentation Deck | 34 slides",
  "authorId": "poseida-therapeutics",
  "authorName": "Poseida Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 34,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "sparse",
  "nDataPoints": 2,
  "notes": "The slide compares autologous (101) vs allogeneic (ALLO1) CAR-T therapy efficacy in tumor reduction.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-35c1-7439-bbdc-1b157563e1ac/20",
  "deckHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac",
  "deckJsonHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac.json",
  "deckAnchorHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "chart",
      "text": "P-BCMA-ALLO1 Samples",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d479801-4ee1-4466-b8ca-8bf1a3641256",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "P-BCMA-101 Patient Samples",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cea9500d-edb4-4d71-8627-4d855f41b6a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "P-BCMA-ALLO1 Reduced Tumor Size at Least as Well as P-BCMA-101 Patient Product in Preclinical Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "165759ca-5003-45c8-bb18-53654800e962",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 11,
      "beatId": "e01fc233-3e21-43db-96cd-4c2c3ec10517",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Description of pipeline and product candidates, including CAR-T and gene therapy programs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}